Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2006 May;189(2):279-87.
doi: 10.1677/joe.1.06351.

Gender differences in the response of CD-1 mouse bone to parathyroid hormone: potential role of IGF-I

Yongmei Wang  1 , Takeshi Sakata, Hashem Z Elalieh, Scott J Munson, Andrew Burghardt, Sharmila Majumdar, Bernard P Halloran, Daniel D Bikle
Affiliations

Gender differences in the response of CD-1 mouse bone to parathyroid hormone: potential role of IGF-I

Yongmei Wang et al. J Endocrinol. 2006 May.

Abstract

Parathyroid hormone (PTH) exerts both catabolic and anabolic actions on bone. Studies on the skeletal effects of PTH have seldom considered the effects of gender. Our study was designed to determine whether the response of mouse bone to PTH differed according to sex. As a first step, we analyzed gender differences with respect to bone mass and structural properties of 4 month old PTH treated (80 microg/kg per day for 2 weeks) male and female CD-1 mice. PTH significantly increased fat free weight/body weight, periosteal bone formation rate, mineral apposition rate, and endosteal single labeling surface, while significantly decreasing medullary area in male mice compared with vehicle treated controls, but induced no significant changes in female mice. We then analyzed the gender differences in bone marrow stromal cells (BMSC) isolated from 4 month old male and female CD-1 mice following treatment with PTH (80 microg/kg per day for 2 weeks). PTH significantly increased the osteogenic colony number and the alkaline phosphatase (ALP) activity (ALP/cell) by day 14 in cultures of BMSCs from male and female mice. PTH also increased the mRNA level of receptor activator of nuclear factor kappaB ligand in the bone tissue (marrow removed) of both females and males. However, PTH increased the mRNA levels of IGF-I and IGF-IR only in the bones of male mice. Our results indicate that on balance a 2-weeks course of PTH is anabolic on cortical bone in this mouse strain. These effects are more evident in the male mouse. These differences between male and female mice may reflect the greater response to PTH of IGF-I and IGF-IR gene expression in males enhancing the anabolic effect on cortical bone.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Gender differences in the response of FFW/BW of tibia to PTH. Results are expressed as mean ±s.d. There were nine females and seven males in the vehicle group, and eight females and six males in the PTH-treated group. a, P<0·05 female control vs male control; b, P<0·05 control vs PTH treatment.
Figure 2
Figure 2
Gender differences in periosteal and endosteal bone formation at the tibiofibular junction as assessed by bone histomorphometry. Results are expressed as mean ±s.d. (A) Periosteal bone formation rate (BFR/BS). (B) Mineral apposition rate (MAR). (C) Endosteal single labeling surface (sLS/BS). (D) Medullary area. (E) Cortical bone area. There are nine females, five males in the vehicle group, and six females, five males in the PTH-treated group. a, P<0·05 PTH treatment vs control; b, P<0·05 female control vs male control.
Figure 3
Figure 3
Gender differences in BMSC colony number and ALP activity (Day 14). Results are expressed as mean ±s.d. (A) Colony number and (B) ALP activity (ALP/cell). n=3 in each group. a, P<0·05 PTH treatment vs control.
Figure 4
Figure 4
Gender differences in the response to PTH with respect to mRNA levels of bone formation markers. (A) IGF-1 and (B) IGF-1R. Results are expressed as percentage of female control, all values have been normalized to GAPDH mRNA levels in the same sample. n=3 in each group. a, P<0·05 PTH treatment vs control.
Figure 5
Figure 5
Gender differences in the response to PTH with respect to mRNA levels of OPG and RANKL. Results are expressed as percentage of female control, and all values have been normalized to GAPDH mRNA levels in the same sample. n=3 in each group. a, P<0·05 PTH treatment vs control.
See this image and copyright information in PMC

References

    1. Alexander JM, Bab I, Fish S, Muller R, Uchiyama T, Gronowicz G, Nahounou M, Zhao Q, White DW, Chorev M et al. 2001. Human parathyroid hormone 1–34 reverses bone loss in ovariectomized mice. Journal of Bone and Mineral Research 16 1665–1673. - PubMed
    1. Bikle D, Majumdar S, Laib A, Powell-Braxton L, Rosen C, Beamer W, Nauman E, Leary C & Halloran B 2001. The skeletal structure of insulin-like growth factor I-deficient mice. Journal of Bone and Mineral Research 16 2320–2329. - PubMed
    1. Bikle DD, Sakata T, Leary C, Elalieh H, Ginzinger D, Rosen CJ, Beamer W, Majumdar S & Halloran BP 2002. Insulin-like growth factor I is required for the anabolic actions of parathyroid hormone on mouse bone. Journal of Bone and Mineral Research 17 1570–1578. - PubMed
    1. Dempster DW, Cosman F, Kurland ES, Zhou H, Nieves J, Woelfert L, Shane E, Plavetic K, Muller R, Bilezikian J et al. 2001. Effects of daily treatment with parathyroid hormone on bone micro-architecture and turnover in patients with osteoporosis: a paire d biopsy study. Journal of Bone and Mineral Research 16 1846–1853. - PubMed
    1. Eisman JA 1999. Genetics of osteoporosis. Endocrine Reviews 20 788–804. - PubMed

Publication types

MeSH terms